Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN51 brain occupancy PET study
NCT06390098Phase 1Completed
- Sponsor
- Asceneuron SA
- Start
- Aug 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ASN51 in Alzheimer's disease (AD), sponsored by Asceneuron SA. Primary endpoints: Regional Total Volume of Distribution (VT) of [18F]-IMA601 in Frontal Lobe, Regional Total Volume of Distribution (VT) of [18F]-IMA601 in Anterior Cingulate and 5 more. Started Aug 2021; status: completed.
02
Drugs
ASN51
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06390098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06390098.